Evidence map›Paper›PMID 27248696›Full record

ArticlePloS one2016

The Dynamics of Disease Progression in Cystic Fibrosis.

Frederick R Adler, Theodore G Liou

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Dynamic modeling of hospitalized COVID-19 patients reveals disease state-dependent risk factors.Journal of the American Medical Informatics Association : JAMIA · 2022
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Microbial Interactions in the Cystic Fibrosis Airway.Journal of clinical microbiology · 2018
    Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Frederick R AdlerDepartment of Mathematics and Department of Biology, University of Utah, Salt Lake City, UT, United States of America.
Theodore G LiouDepartment of Internal Medicine, University of Utah, Salt Lake City, UT, United States of America.
University of Utah · US

Funding

Explanatory models of CF Survival, Infection and Intermediate Clinical OutcomesR01HL125520 · NHLBI · UNIVERSITY OF UTAH · PI LIOU, THEODORE GEH-LU · 2015 to 2018
$1.4M
NHLBI NIH HHS R01 HL125520
6 · The paper itself

Abstract

In cystic fibrosis, statistical models have been more successful in predicting mortality than the time course of clinical status. We develop a system of partial differential equations that simultaneously track mortality and patient status, with all model parameters estimated from the extensive and carefully maintained database from the Cystic Fibrosis Foundation. Cystic fibrosis is an autosomal recessive disease that leads to loss of lung function, most commonly assessed using the Forced Expiratory Volume in 1 second (FEV1%). This loss results from inflammation secondary to chronic bacterial infections, particularly Pseudomonas aeruginosa, methicillin-sensitive Staphylococcus aureus (MSSA) and members of the virulent Burkholderia complex. The model tracks FEV1% and carriage of these three bacteria over the course of a patient's life. Analysis of patient state changes from year to year reveals four feedback loops: a damaging positive feedback loop between P. aeruginosa carriage and lower FEV1%, negative feedback loops between P. aeruginosa and MSSA and between P. aeruginosa and Burkholderia, and a protective positive feedback loop between MSSA carriage and higher FEV1%. The partial differential equations built from this data analysis accurately capture the life-long progression of the disease, quantify the key role of high annual FEV1% variability in reducing survivorship, the relative unimportance of short-term bacterial interactions for long-term survival, and the potential benefits of eradicating the most harmful bacteria.

Indexed as

Disease ProgressionBurkholderiaCarrier StateCystic FibrosisHumansPseudomonas aeruginosaStaphylococcus aureus

Identifiers

PMID27248696
PMCPMC4889102
OpenAlexW2412814739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.